Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238724 | 0.80 | TSHR (0.39) | SMN1; SMN2ADORA3SLC6A3KMT2AMAPT | |
| SCHEMBL1063493 | 0.74 | ADORA3 (0.50) | SMN1; SMN2ADORA3SLC6A3MAPTHSD17B10 | |
| SCHEMBL2649098 | 0.73 | SMN1; SMN2 (0.39) | SMN1; SMN2ADORA3SLC6A3HTTHSD17B10 | |
| SCHEMBL2649056 | 0.73 | ALDH1A1 (0.40) | SMN1; SMN2MAPTHTTHSD17B10GAA | |
| SCHEMBL3474793 | 0.69 | ADORA3 (0.55) | SMN1; SMN2ADORA3SLC6A3 | |
| SCHEMBL1636834 | 0.67 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTHTTHSD17B10GAA | |
| Hydrochloric Acid SCHEMBL28327830 | 0.67 | ADORA3 (0.53) | SMN1; SMN2ADORA3SLC6A3 | |
| SCHEMBL1240657 | 0.67 | SMN1; SMN2 (0.53) | SMN1; SMN2ADORA3SLC6A3KMT2AMEN1 | |
| Bromide SCHEMBL1636830 | 0.66 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTHTTHSD17B10GAA | |
| SCHEMBL2650487 | 0.66 | ADORA3 (0.39) | SMN1; SMN2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | SMN1; SMN2 4814/4885ADORA3 3095/4885SLC6A3 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.